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OBJECTIVES: To measure costs associated with treatment failure among patients
with moderate or complicated CA-MRSA skin infections. METHODS: This was a
prospective, observational study in 4 primary care clinics within the South Texas
Ambulatory Research Network (STARNet). Health care providers collected clinical
data, wound swabs, and 90-day follow-up information. Patientswere considered to
have moderate or complicated infections if they had a lesion 5 cm in diameter,
diabetes mellitus, or both. Patients experienced treatment failure if any of the
following occurred within 90 days of their initial visit: 1) change in antibiotic ther-
apy; 2) subsequent need for incision and drainage [I&D]; 3) subsequent positive
MRSA culture; or 4) hospital admission. The cost analysis was performed from the
perspective of the health insurance payer. Medical costs were derived using esti-
mates from the Agency for Healthcare Research and Quality. National Average
Drug Acquisition Costs, obtained from the Centers for Medicare and Medicaid Ser-
vices, were used to estimate drug costs. All costs were adjusted to 2011 United
States dollars using national medical-care inflation rates. RESULTS: One-third of
patients with moderate or complicated CA-MRSA infections experienced treat-
ment failure (n11/36, 31%). Of the 11who failed therapy, 91% required a change in
antibiotic regimen at an additional mean cost of $4 per person. Eighty percent of
patients who required a change in antibiotics received trimethoprim-sulfame-
thoxazole as initial antibiotic therapy. Patients frequently required the addition of
either clindamycin (50%) or doxycycline (30%) to their initial antibiotic regimen.
Additional I&D procedures were necessary in 27% of patients at a mean cost of
$2130 per person. Finally, 9% of patients required hospitalization at a mean cost of
$17,590 per person. The overall mean cost of treatment failure was $2184 per pa-
tient. No adverse drug events were reported. CONCLUSIONS: One-third of adult
outpatients with moderate or complicated CA-MRSA skin infections will experi-
ence treatment failure at a mean cost of $2184 per patient.
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OBJECTIVES: Streptococcus pneumoniae is one of the most important etiologic
agents of both, respiratory infections and systemic invasive diseases, with signif-
icative rates of morbidity and mortality in the elderly, which represents an eco-
nomic burden. There are few published studies describing the cost of care for
elderly patientswith pneumococcal disease in LatinAmerica. The goal of this study
is to estimate the directmedical costs of the acute phase of pneumococcal diseases,
it=s complications and sequelae in elderly patients in Mexico, regarding the per-
spective of the Social SecurityMexican Institute (IMSS).METHODS: Resource use in
the treatment of pneumonia, bacteremia, meningitis and acute otitis media (AOM)
was extracted from 112 clinic files of patients 50 years with confirmed diagnosis
of pneumococcal disease, treated at Guadalajara, Monterrey and Mexico City hos-
pitals, using a micro-costing approach (bottom-up strategy). Items included in the
analysiswere: drugs, laboratory tests, outpatient and inpatient care, rehabilitation,
procedures and surgical interventions. Resource use for the treatment of compli-
cations and sequelae were derived trough a Delphi panel (n13, infectologists,
pediatricians and internist physicians, IMSS). Concordance index for the Delphi
panel resultswas estimated. The unit cost ofmedical resourceswas extracted from
institutional source. RESULTS: The estimated direct cost (2011 US) associated to
acute phase of pneumococcal diseases were: AOM $323, outpatient pneumonia
$172, inpatient pneumonia $4,718, bacteremia $7,698, meningitis $10,687. Cost of
complications (such as systemic, respiratory, cardiac, etc.) was: AOM US$671, out-
patient pneumonia US$1,502, inpatient pneumonia US$5,157, bacteremia
US$11,267,meningitis US$8,060. The costs of sequelae (such as cardiac, neurologic,
auditive, etc.) were: AOM US$593, outpatient pneumonia US$18, inpatient pneu-
monia US$1,560, bacteremia US$ 1,573, meningitis US$13,297. CONCLUSIONS: The
high institutional costs associated with pneumococcal disease, as well as its com-
plications and sequelae,merit that decisionmakersmaintain and promote preven-
tion policies for this disease in the elderly.
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OBJECTIVES: To estimate the economic cost of probable viral diarrhea in children
less than 5 years old in a 130,800-chlidren cohort in Colombia. METHODS: A de-
scriptive study of economic costs was made. A database of 2010 attentions of a
Health Insurer was analyzed. It has 1,254,000 affiliates (130,800 children under 5
years), resident in 12 Colombian departments. The cases were identified using
international classification of diseases version 10 (A080, A083, A084, A085, A09X).
The types, quantity and frequency of use of health services weremeasured. Types,
quantity and frequency of use of health services were measured. The prices of
services were extracted from the Colombian official prices. Median (interquartile
range: IQR) of direct cost and average length of stay (LOS) in days were calculated.
The costs were calculated for hospitals by levels of complexity to prices of 2011 and
converted to American dollars. RESULTS: A total of 1456 cases of probable viral
diarrheawere identified in children less than five years old. 184 cases (12.64%)were
outpatient. Of inpatients, 42.9% were low level of complexity (LOS: 4.4), 42.8% were
middle of complexity (LOS: 4.1), and 1.3% were high level of complexity (LOS: 3.4).
0.2% of patients required Intensive Care Unit (LOS: 12.6). The median of cost per
outpatient casewasUSD$82.8 (IQR: 51-483); themedian of cost per inpatient case of
middle level of complexity was USD$94 (IQR: 17.4-296.6); and in high level of com-
plexity was US$130.4 (IQR: 81.6-222.6) and in ICU US$3.341 (IQR: 1862-4821). The
total cost of cases was US$182,000.3. CONCLUSIONS:Most probably viral diarrhea
cases are mild with low average of stay. Despite the introduction of the rotavirus
vaccine in early 2009, probably viral diarrhea in children under 5 years in Colombia
has a significant burden of disease in this cohort.
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OBJECTIVES: . To estimate the economic cost of bacterial pneumonia in children
less than 5 years old in a 130,800-chlidren cohort in Colombia. METHODS: . A
descriptive study of economic costs was made. A database of 2010 attentions of a
Health Insurer was analyzed. It has 1,254,000 affiliates (130,800 children under 5
years), resident in 12 Colombian departments. The cases were identified using
international classification of diseases version 10 (J189, J180, J159, J159, J188, J158,
J851, J18, A409, P361, A408). The types, quantity and frequency of use of health
services were measured. Types, quantity and frequency of use of health services
were measured. The prices of services were extracted from the Colombian official
prices. Median (interquartile range: IQR) of direct cost and average length of stay
(LOS) were calculated. The costs were calculated for hospitals by levels of complex-
ity to prices of 2011 and converted to American dollars. RESULTS: . A total of 1545
cases of probable bacterial pneumoniawere identified in children less thanfive years
old (56.7% inunder-2 years). 309 cases (20%)wereoutpatient.Of inpatients, 15.9%were
low level of complexity (LOS: 2.3), 78.1%weremiddle of complexity (LOS: 5.3), and 3.1%
were high level of complexity (LOS: 7.1). 2.9% of patients required Intensive Care Unit
(LOS: 18). The median of cost per outpatient case was USD$98 (IQR: 73–147); The me-
dian of cost per inpatient case of middle level of complexity was USD$254 (IQR: 156-
284); and in high level of complexity was US$488.6 (IQR:135.5-1064.7) and in ICU
US$5,016.5 (IQR:2,568-6,754). The total cost of caseswasUS$871.809.CONCLUSIONS: .
The cases of probable bacterial pneumonia in children under 5 years in Colombia are
a serious public health problem. Most cases are in under-2 years and inpatients of
hospitals of middle level of complexity.
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OBJECTIVES: To examine the economic evidence base, identify gaps in the evi-
dence, and propose potential areas of future enquiry into the economics of rubella,
congenital rubella syndrome (CRS) and rubella vaccination to support the planned
global expansion of rubella-containing vaccine (RCV) and the push towards poten-
tial rubella elimination and eradication. METHODS: A MEDLINE search was con-
ducted of articles published between 1980 and 2010 on costs of rubella and CRS
treatment and the costs, cost-effectiveness or cost-benefit of rubella vaccination.
The design and results of studies were reviewed and categorized by the country
income level. Gaps in the evidence of the costs of rubella and CRS and cost-effec-
tiveness of rubella vaccination and the potential for rubella eradication were
identified. RESULTS: Twenty-five studies were identified. Of the nineteen studies
conducted in high-income countries, 5 were cost analyses, 3 were cost-effective-
ness analyses and 11 were cost-benefit analyses. Of the five studies conducted in
uppermiddle-income countries, fourwere cost analyses and onewas a cost-benefit
study. A single study was conducted in a lower middle-income country and was a
cost-benefit analysis. No studies were conducted in low-income countries. In the
review, CRSwas estimated to cost between $1,994 and $13,482 per case annually or
between $50,000 and $63,990 lifetime in middle-income countries and $98,734 life-
time in high-income countries. The review also found that rubella vaccination
programs had favorable cost-effectiveness, cost-utility, or cost-benefit ratios in
high-income countries and middle-income countries. CONCLUSIONS: Rubella is
costly and rubella vaccination programs are highly cost-effective. However, in or-
der for research to support the drive towards rubella elimination and eradication,
additional studies are required in low-income countries, to tackle methodological
limitations, and determine the most cost-effective strategies for rubella vaccina-
tion.
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OBJECTIVES: Current guidelines for the treatment of acute bacterial skin and skin
structure infections (ABSSSI) recommend aggressive treatment, including hospi-
talization for patients whose infection is progressing despite empiric antibiotic
therapy. In such cases potentially involving S. aureus, guidelines suggest that cli-
nicians should use agents effective againstMRSA because of the high prevalence of
community-associated MRSA strains. This study attempts to ascertain the US eco-
nomic burden and near-term outcomes of in-hospital treatment of ABSSSI during
recent years. METHODS: Using the Premier Hospital Database, hospitalization re-
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cords were reviewed from 2007 to 2009 to extract patients with principle diagnosis
of ICD-9 codes for cellulitis, abscess, postoperative and traumatic wound infec-
tions, and other conditions related to ABSSSI. We assessed inpatient utilization in
terms of LOS and ICU time, and inpatient costs stratified by initial antibiotic treat-
ment. We also assessed the frequency of in-hospital mortality and empiric treat-
ment failure. RESULTS: Inpatient treatment of ABSSSI increased by 15.4% from
2007 to 2009. In 2009, 110,457 ABSSSI patients were admitted to Premier hospitals,
with 65% admitted through the ER. The initial antibiotic treatment was vancomy-
cin (49.9%) and clindamycin (15.9%). The average LOS was 5.3 days. The average
cost per stay was $8000. The most costly departmental charges were room/board
($1000) and pharmacy ($650). 17.2% of patients failed on initial antibiotic treatment,
resulting in additional LOS of 5 days and $6000 per stay on average. With approx.
750K admissions for ABSSSI in the United States, this extrapolates to a US hospital
economic burden of $6 billion/yr. CONCLUSIONS: The economic burden of hos-
pitalization for ABSSSI in the United States is significant. Antibiotic treatments
offering the possibility of treating a greater proportion of patients currently hospi-
talized in an ambulatory or observational setting by avoiding or shortening hospi-
tal stays may significantly reduce the cost to the US health care system.
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OBJECTIVES: Congenital cytomegalovirus (CMV) infection during pregnancy are a
serious, yet not well recognized health problem. The aim of our study is to assess
the annual cost of diagnosis and prevention of congenital cytomegalovirus infec-
tion by Cytotect in Hungary.METHODS:We built a model on estimating the costs.
Data on deliveries derived from the database of the Hungarian Central Statistical
Office. Cost items were calculated according to the standard reimbursement list of
the Hungarian National Health Insurance Fund, the only health care financing
agency in Hungary. The number of livebirths was 90,335 in 2010 in Hungary. The
cost of CMV Ig-test was 2 Euro. Average bodyweight was 80 kg, the average dosis of
Cytotec was 8000 unit or 80 ml per patient with a cost of 8 Euro per ml. CMV-
seronegative women (40 % of all deliveries) are the high risk group applying 4 tests
during pregnancy. Seroconversion rate was 1 %. RESULTS: For all pregnant women
(N90335), the total annual cost of diagnosis of congenital cytomegalovirus infec-
tion was calculated 180,670 Euro (or 54.2 million Hungarian Forint). For CMV-sero-
negative high risk women (N36134) the total annual cost of diagnosis was as-
sessed 289072 Euro (or 86.7 million Hungarian Forint). The cost of prevention of all
women with primary infection during pregnancy was 2.89 million Euro (or 867.2
million Hungarian Forint). CONCLUSIONS: Both the diagnosis and prevention of
congenital cytomegalovirus (CMV) infection during pregnancy represents a reason-
able cost in Hungary. Further study should focus on the effectiveness of preven-
tion.
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OBJECTIVES: The use of combined tetanus toxoid, reduced diphtheria toxoid, and
acellular pertussis vaccine (Tdap) in pregnant and postpartum women provides
personal protection and may reduce the risk of transmission of pertussis to their
young infants. The study seeks to assess the economic benefits associated with a
hospital-based postpartum Tdap vaccination strategy. METHODS: A decision tree
model was constructed to calculate the potential cost-benefit of this strategy from
a health care system or societal perspective. Probabilities and costs were derived
from published literature, Centers for Disease Control and Prevention data, and
expert recommendations. The maternal vaccination protection period for infants
was defined as 7 months, as the infants do not receive a full series of pertussis
immunization before 6 months of age, with 1 month added for maximal develop-
ment of immunity. 10-year vaccine protection for birth mothers was estimated in
the model. All cost estimates were inflated to year 2010 US dollars and discounted
at a 3% annual discount rate. RESULTS: From a societal perspective, the average
costs per vaccinated and unvaccinated mother were estimated at $132.92 and
$232.75, respectively. Our model suggests an expected net benefit (ENB) of $99.83
per postpartum vaccinated mother. The overall societal benefits in the cohort of
U.S. birth mothers ranged from $89.8  $287.5 million, depending on the vaccine
coverage rate. If including direct medical costs only, the ENB was estimated at
-$27.26 per vaccinatedmother, suggesting that this strategy is not cost-saving from
a health care system perspective. Annual incidence in birth mothers and Tdap
efficacy exhibited substantial impact on the model from one-way and two-way
sensitivity analyses. CONCLUSIONS: Postpartum Tdap vaccination is likely to gen-
erate net benefits in the base case from a societal perspective, if the annual inci-
dence of pertussis among birth mothers exceeds 140 cases per 100,000.
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BACKGROUND: In US treatment guidelines, efavirenz (EFV) is the preferred non-
nucleoside reverse transcriptase inhibitor (NNRTI) for first-line treatment of HIV. In
the ECHO and THRIVE trials comparing EFV with another NNRTI, rilpivirine (RPV),
both medications had similar rates of virologic suppression at 96-weeks; however,
RPV had higher rates of virologic failure and drug resistance and lower rates of
discontinuation due to adverse events. OBJECTIVES: To estimate the cost-effec-
tiveness of EFV versus RPV in first-line HIV treatment in the US. METHODS: A
Markovmodel with 14 health states was constructed to estimate 10-year costs and
clinical outcomes from a US payer perspective for antiretroviral naïve HIV patients
initiating EFV or RPV. First-line efficacy data came from 96-week results of the
ECHO and THRIVE trials, which compared EFV and RPV, both in combination with
two nucleos(t)ide reverse transcriptase inhibitors. Other clinical inputs, mortality
rates and costs (2011 US$) came from published sources. Subsequent therapy lines
(second, third, non-suppressive) were based on US treatment guidelines and com-
mon to both treatment arms. Robustness of study results was assessed in sensi-
tivity analyses that varied model inputs by 25%. RESULTS: In the base case, total
costs over 10 years were lower for EFV versus RPV ($214,031 versus $222,090). Life
expectancy (8.44 years) and life years without AIDS (8.40 years) were the same and
life years in virologic suppression were similar (EFV 7.87 years, RPV7.86 years).
EFV was modestly cost-saving versus RPV in terms of incremental cost-effective-
ness per life-year gained, per life-year gained in viral suppression, and per life-year
gainedwithout AIDS. In sensitivity analyses, EFV remained cost-saving versus RPV
more than 90% of the time, demonstrating the robustness of study results.
CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be modestly
cost-saving compared with RPV in HIV patients initiating first-line treatment in
the US.
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OBJECTIVES: To evaluate the comparative cost-effectiveness of sequential i.v./p.o.
CAP treatment with moxifloxacin versus amoxicillin/clavulanic acid (AMCLA),
ceftriaxone amoxicillin/clavulanic (CEFAMCLA) acid and cefotaxime macro-
lides (COMB) in adult patients. METHODS: Patients were randomized in four
groups. MOX group received moxifloxacin 400 mg i.v. once-daily with further
switch to p.o. formulation 400 mg daily. AMCLA group received amoxicillin/clavu-
lanic acid 1200 mg i.v. once-daily with further switch to p.o. formulation 1000 mg
twice-daily. CEFAMCLA group received ceftriaxone 1000 mg i.v. once-daily with
further switch to amoxicillin/clavulanic acid 1000 mg p.o. twice daily. COMB group
received either cefotaxime 1000 mg i.m. 3 times per day as monotherapy or in
combination with oral azithromycin or clarithromycin. Efficacy and safety criteria
were evaluated according to clinical data, laboratory tests and X-ray examination.
Cost-effectiveness analysis was performed. RESULTS: MOX group included 30 pa-
tients, mean age 33.616.5 years; AMCLA group included 30 patients, mean age
27,115,4 years; CEF/AMCLA group included 47 patients, mean age 23,59,6 years;
COMB group included 50 patients, mean age 26.515.6 years. The efficacy of treat-
ment and in-hospital stay duration were: 96.7% and 15.12.1 days in MOX group,
93.3% and 17,02,7 days in AMCLA group, 95.7% and 16,43,4 days in CEF/AMCLA
group, 88.0% and 18.23.7 days in COMB group. Direct medical costs including
antibacterial treatment and in-hospital days were $1536 in MOX, $1540 in AMCLA,
$1502 in CEF/AMCLA and $1671 in COMB group. CERMOX 1589$, CERAMCLA1650$,
CERCEF/AMCLA1570$, CERCOMB 1899$. CONCLUSIONS: Sequential CAP treatment
with moxifloxacin compared to other alternatives in adult patients is the most
effective, convenient and compliant therapy. In terms of cost-effectiveness, it
dominants over AMCLA and COMB treatment and have the comparable costs with
CEFAMCLA group.
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OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of geno-
type 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effective-
ness of TVR/PR therapy compared to PR alone in treatment-naïve and previously
treated G1 chronic HCV patients. Cost-effectiveness is considered in terms of in-
cremental cost per quality-adjusted life-year (QALY) gained from the perspective of
the NHS in Scotland. METHODS: Two Markov models were developed to evaluate
treatments studied in TVR phase III clinical trials: TVR response-guided therapy of
12weeks of TVRwith PR [24weeks PR for patients achieving an extended rapid viral
response (eRVR), 48 weeks of PR for patients not achieving an eRVR] for treatment-
naïve patients; 12 weeks of TVR in combination with 48 weeks of PR therapy for
treatment-experienced patients. SVR rates of 75% and 44% for TVR/PR and PR alone
respectively are taken from the TVR12/PR and PBO/PR treatment arms in the AD-
VANCE trial. SVR rates of 83%, 59% and 29% for TVR/PR and 24%, 15% and 5% for PR
alone in prior relapse, prior partial response and prior null response patients, re-
spectively are taken from the TVR12/PR and PBO/PR treatment arms in the REALIZE
trial. RESULTS: The analysis shows higher costs and improved outcomes associ-
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